Related Experiment Videos
EVI1 expression in acute myeloid leukaemia
S E Langabeer1, J R Rogers, G Harrison
1Department of Haematology, University College London Hospitals and Medical School, London, UK. s.langabeer@ucl.ac.uk
British Journal of Haematology
|February 13, 2001
Summary
EVI1 transcript expression is frequent in Acute Myeloid Leukaemia (AML) but not linked to poor prognosis unless 3q26 abnormalities are present. Screening for EVI1 may not aid treatment stratification in AML without these specific genetic changes.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Genetics
Background:
- Acute Myeloid Leukaemia (AML) with 3q26 cytogenetic abnormalities is linked to EVI1 overexpression, dysmegakaryopoiesis, and poor prognosis.
- EVI1 gene deregulation is a known factor in certain hematologic malignancies.
Purpose of the Study:
- To screen for EVI1 transcripts in a large cohort of Acute Myeloid Leukaemia (AML) patients.
- To investigate the association of EVI1 expression with 3q26 abnormalities, dysmegakaryopoiesis, and patient outcomes in AML, including Acute Promyelocytic Leukaemia (APL).
Main Methods:
- Screening for EVI1 transcripts using molecular techniques.
- Analysis of cytogenetic abnormalities (3q26).
- Evaluation of clinical data, including patient outcomes and presence of dysmegakaryopoietic features.
Main Results:
- EVI1 transcripts were detected in 7/10 cases with 3q26 abnormalities and 23/326 cases without 3q26 abnormalities.
- EVI1 expression in AML cases lacking 3q26 abnormalities was not associated with dysmegakaryopoiesis or poor prognosis.
- EVI1 deregulation, while rare, was found to be a relatively frequent event in AML overall, including one APL case.
Conclusions:
- EVI1 transcript screening is unlikely to assist in treatment stratification for AML patients lacking 3q26 abnormalities.
- EVI1 deregulation is a more common event in AML than previously recognized, even in the absence of 3q26 abnormalities.